Compare Crispr Therapeutics AG (CRSP) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Wynn Resorts, Limited — how do they compare? Crispr Therapeutics AG trades at $56.56 (market cap $5.47B), while Wynn Resorts, Limited trades at $81.66 (market cap $8.41B). The key difference: Wynn Resorts, Limited is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1.22% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 76 Days and Wynn Resorts, Limited for 76 Days on average.
| CRSP | WYNN | |
|---|---|---|
Market Cap | $5.47B | $8.41B |
Volume | 3,381,169 | 5,025,733 |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $133.34 |
52-Week Low | $44.34 | $81.66 |
Typical Hold Time | 76 Days | 76 Days |
Enterprise Value | $3.89B | $18.65B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $56.56, up 8.33% today, with a bullish technical signal and strong analyst support. The stock shows improving cash flow trends despite negative profitability, with net cash flow turning positive in 2025. Recent news highlights pipeline progress, including CASGEVY commercialization and upcoming clinical data, driving investor optimism.
Outlook remains speculative with high growth potential from gene-editing advancements, but significant risks persist from cash burn and unprofitability. Wall Street consensus is bullish with a $67.83 price target, though execution on pipeline milestones is critical for sustained upside.
Wynn Resorts (WYNN) trades at $81.66, down 3.05% today, reflecting near-term pressure despite a recent Q2 2026 earnings beat. The stock shows a mixed technical picture with bearish moving averages but bullish oscillators, while fundamentals reveal solid revenue growth to $7.14B in 2025 but declining net margins. Recent news highlights institutional buying interest and a $900M senior notes offering to fund expansion, including the Wynn Al Marjan Island project targeting a September 2027 opening.
The outlook is cautiously optimistic, with a consensus price target of $132.36 implying significant upside, driven by Macau recovery and new project potential. Key risks include high debt levels, rising capex, and margin pressure in U.S. operations. Investors should weigh strong analyst buy ratings (64%) against execution risks and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
